Uncertainty and Distress Associated with Myelodysplastic Syndromes (MDS)

Joan M. Latsko  
DNP, CRNP, OCN, AOCNP  
Western Pennsylvania Cancer Institute  
Pittsburgh, Pennsylvania  
Member, MDS Foundation International Nursing Leadership Board

Myelodysplastic Syndromes are a group of chronic hematologic diseases associated with a poorly functioning bone marrow and ineffective hematopoiesis resulting in peripheral blood cytopenias and potential conversion to acute leukemia. MDS afflicts the elderly with an average age of 76 years (range 65–85 years), more men than women (2:1), and more Caucasians compared to other races (3:1). The incidence of MDS, according to the most recently published SEER data, is estimated to be 4 cases per 100,000 population per year or 30,000 to 40,000 per year as compared to previous data that suggested the incidence to be only 10,000 to 20,000 per year. However, incidence and prevalence rates are changing rapidly due to earlier referrals to hematology clinicians, improved diagnostic procedures and the increased incidence of treatment-related MDS, which occurs as a result of previous radiation and chemotherapy exposures.1,2

 Patients diagnosed with a potentially terminal disease such as MDS, face many challenges related to the disease: uncertainty, distress, and quality of life to name a few. Patients have individual responses to stressors related to the diagnosis of MDS, treatment, response, survival or the fear of death. Healthcare clinicians may lack sufficient time to clearly define this complex disease. Because MDS is a fairly uncommon disease, they may have limited experience with MDS patients and be less able to assess the impact of uncertainty and distress on the patient. Patients tend to underestimate the symptoms and impact of

<table>
<thead>
<tr>
<th>Contents</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>News From The Foundation</td>
<td>5</td>
</tr>
<tr>
<td>Meeting Announcements</td>
<td>7</td>
</tr>
<tr>
<td>Drug News</td>
<td>8</td>
</tr>
<tr>
<td>Patient Forums and Support Groups</td>
<td>10</td>
</tr>
<tr>
<td>Patient Tributes</td>
<td>13</td>
</tr>
<tr>
<td>MDS Centers of Excellence</td>
<td>15</td>
</tr>
<tr>
<td>Discussions in Therapy</td>
<td>18</td>
</tr>
<tr>
<td>Information on Clinical Trials</td>
<td>19</td>
</tr>
<tr>
<td>Educational Resources</td>
<td>21</td>
</tr>
<tr>
<td>Contributions to the Foundation</td>
<td>22</td>
</tr>
<tr>
<td>In Memoriam</td>
<td>24</td>
</tr>
<tr>
<td>General Information</td>
<td>28</td>
</tr>
</tbody>
</table>

their uncertainty and distress, and often minimize their distress when speaking to the clinical team. There are differences among a patient’s healthcare clinician’s, as well as a nurse’s attitudes and beliefs concerning uncertainty and distress. This may also influence the provision of appropriate psychological and psychosocial care.\(^3\)

Patients with MDS are faced with a number of challenges including the uncertain clinical course of their disease. Constant distress from uncertainty can lead to additional conditions such as anxiety and depression, with an ultimate impact on quality of life. Uncertainty is rooted in the perception of outcomes or meaning of a situation.\(^4\) These perceptions challenge the sense of confidence to control the type and approaches towards adaptation to the uncertainty.\(^4\)\(^-\)\(^7\) However, uncertainty and distress are not synonymous with a patient’s quality of life, but rather separate entities, which will ultimately affect the individual’s quality of life.

Distress is recognizable as a psychological reaction to the stress of the cancer diagnosis. MDS is classified as a bone marrow malignancy thus, a cancer diagnosis.\(^8\) Distress experienced by MDS patients is comprised of denial, depression, despair, loss, hopelessness, and a fear of the known or unknown. In addition, the inability to continue employment, tend to business affairs, or interact socially with family or friends in the usual manner are contributing factors. Finally, the patient’s attributes (age, sex, race, religion, living locale, etc.), disease attributes (length of diagnosis, current treatment regime, treatment response, etc.), social system attributes (family, friends, support groups, etc.) and timing (disease interval, seasons, holidays, etc.) may have tremendous implication for uncertainty and distress among the MDS population. Consequently, continual disease uncertainty and distress experienced by the MDS patient will ultimately disrupt their overall quality of life.

The combination of these factors explains in part the wide variability in experiences for each patient with MDS. The lack of adequate knowledge about the disease may be due to general deficiencies in disease information, misinterpretation of the medical language, and a social misunderstanding of the disease. The aura of uncertainty relates to the constraints of the disease and the relative chronicity of the disease. However, the overall classification of MDS is not in the same context of other chronic diseases, as it has classification as a bone marrow malignancy. In addition, the variable symptoms of physiological well versus non-well in MDS patients is not congruent with the overall chronicity of the disease, including extended periods of stability, remission, potential relapse or progression to acute leukemia. Finally, disruption of emotional stability may result from the continual fear of complications including serious or fatal cytopenias and conversion to acute leukemia.

The uncertainty of MDS as a disease process challenges the patient to find meaning in the disease process and develop effective coping behaviors.

The uncertainty of MDS as a disease process challenges the patient to find meaning in the disease process and develop effective coping behaviors. The patient’s uncertainty relates to their own internalized perceptions of the “cancer” diagnosis, variability in symptoms unpredictability of the disease course, erratic responses to treatment interventions and a potential terminal outcome. The individual MDS patient’s response to uncertainty will vary according to their perception of their situation. Some will see their situation in a positive way and will develop and use effective coping strategies. Other patients may find this more challenging and will have difficulty developing effective coping strategies. This more negative view of the diagnosis (danger) and view of uncertainty may lead to a more emotional response and greater difficulty adapting to the challenges faced.

Research suggests there are many factors that contribute to each individual patients response to the uncertainty of a cancer diagnosis.\(^9\)\(^-\)\(^11\) Uncertainty has the potential to occur with any individual, whether in health or illness, patients, caregivers or parents of ill children. Coping strategies to deal with uncertainty were evaluated through patterning over time, supportive care and communication indicating a need for healthcare clinician support throughout the uncertainty event.\(^12\)\(^-\)\(^13\) Individuals dealing with either acute or chronic diseases experience uncertainty with many concerns, including the sequelae of the disease or disorder, symptoms, knowledge, and treatment responses as well as their future and potential mortality. Individuals have a very personal response to perceived stress, stressors, diagnosis, treatment, response and adaptation.

The psychosocial complication of distress is a prevalent problem when patients are diagnosed and facing treatments for MDS. Distress can impair the patients subsequent decision-making strategies, compliance and overall treatment response.\(^14\) Distress research has identified a number of issues associated with relationships to age, sex, race, religion, as well as numerous other physical, psychological, personal, environmental and social variables, which affected coping skills among patients diagnosed and treated for cancer.\(^15\)\(^-\)\(^21\) Three studies reviewed research instruments for evaluating and detecting distress, while determining that all three instruments identified the concept of distress. However, identification does not necessarily require a tool or instrument, but does require the time and effort for effective assessment and intervention on the part of the clinician.\(^22\)\(^-\)\(^24\)
Current research on MDS has primarily focused on aspects of the disease, including pathology, treatment options, treatment outcomes and quality of life. The goals for treatment of MDS are to control symptoms, improve quality of life, improve overall survival and decrease progression of the disease to acute leukemia. A literature review identified studies related to quality of life with the disease, the treatment and responses. One published study evaluated common troublesome symptoms and the impact on quality of life. The study confirmed that MDS patients experience a broad range of symptoms and impaired health with fatigue being the most debilitating factor. Three published studies evaluated the influence of the MDS patient’s hemoglobin level and transfusion status on quality of life. These studies determined that quality of life was impaired secondary to symptoms of fatigue and dyspnea related to anemia, hemoglobin less than 10 grams/deciliter and the need for chronic transfusion therapy. Ultimately, the chronicity of fatigue associated with MDS will only enhance the uncertainty and distress experienced by patients.

An additional eight published studies evaluated quality of life in MDS patients receiving specific treatments or therapies including growth factors, azacitidine, decitabine, and lenalidomide. The results of these studies indicated that enhancement of the MDS patient’s quality of life was associated with improvement in the patient’s anemia and subsequent transfusion independence secondary to an ongoing response by active treatment for the disease.

However, a clinical response to a pharmacologic treatment does not necessarily equate to an improvement in the uncertainty, distress or overall quality of life. A patient may have a physical, laboratory or pathological improvement, but not necessarily a psychological improvement to the prescribed treatment. The management of psychosocial coping proficiency in the face of illness or disease is a subcomponent in a majority of research instruments evaluating quality of life. Quality of life is an imperative factor when evaluating patient responses in the diagnosis and treatment of chronic, malignant and potentially life-threatening diseases such as MDS. However, the psychosocial aspects of distress, specifically uncertainty and distress, lack full incorporation within the instruments utilized for research associated with quality of life.

MDS is an increasingly common hematologic disorder that affects the older individual (age >60) with a conglomerate of physical, emotional, psychological and psychosocial components. The uncertainty associated with the MDS diagnosis is unique. Strategies for assessment of each patient and development of an individualized plan for support will require consideration of the individual patient attributes, the stage of disease, expected chronicity vs. terminality of the disease, and the ability of the patient to develop effective coping strategies. However, uncertainty and distress are not synonymous with a patient’s quality of life, but rather separate entities, which will ultimately affect their quality of life. Thus, future research is needed to more clearly define the level of uncertainty and degree of distress faced by patients with MDS. Establishment of a multidisciplinary approach will promote more effective assessment of the patient’s uncertainty, prompt intervention by members of the clinical team and may improve their overall quality of life.

References
3. Rosenthal E. Psycho-oncology pioneer Jimmie Holland on her fight to have cancer patients’ distress recognized. Oncology Times. 2007;29(20):8–12


From The Foundation

“helping you give hope...”

The MDS Foundation is a multi-disciplinary, international organization devoted to support, research, treatment, and education for patients, caregivers, physicians, and other health care providers. The organization is based upon the premise that international cooperation will accelerate the process leading to the control and cure of these diseases.

Please join us as a member of the Foundation.

JOIN US AS AN MDS CENTER OF EXCELLENCE

Apply for The Centers of Excellence Program:

Would you like your treatment center to become part of the Foundation’s research network and referral system for MDS patients?

Please call us for more information and an application.

MDS FOUNDATION PUBLICATIONS

The MDS Foundation provides referrals to our Centers of Excellence and the following information to physicians and patients, free of charge:

- The MDS News
- The MDS Messenger (Free E-News)
- Patient Diary
- What Does My Bone Marrow Do?
- Understanding Myelodysplastic Syndromes: A Patient Handbook*
- Transfusion-Dependent Iron Overload and MDS: A Handbook for Patients*
- It Takes Time to Realize Your Goals
- Insurance and Reimbursement Resources for MDS Patients

*The MDS Patient Handbooks and Iron Overload booklets are available in English and the following languages:

- Arabic
- Czech
- Dutch
- French
- German
- Greek
- Hebrew
- Hungarian
- Italian
- Japanese
- Polish
- Portuguese
- Romanian
- Russian
- Spanish
- Swedish
- Turkish
- Arabic
- Czech
- Dutch
- French
- German
- Greek
- Hebrew
- Hungarian
- Italian
- Japanese
- Polish
- Portuguese
- Romanian
- Russian
- Spanish
- Swedish
- Turkish

NEW FROM THE FOUNDATION


FOUNDATION INITIATIVES FOR 2011 AND BEYOND...

- WORLDWIDE PATIENT QUALITY-OF-LIFE FORUMS
- WORLDWIDE PATIENT SUPPORT GROUPS
- INTERNATIONAL NURSING LEADERSHIP BOARD

VISIT US ON FACEBOOK AND TWITTER!

facebook
twitter

VISIT OUR WEBSITE AND LINK TO OUR EDUCATIONAL RESOURCE CENTER:

www.mds-foundation.org
About the Foundation

Who Are We?
The Myelodysplastic Syndromes Foundation, Inc., was established in 1994 by an international group of physicians and researchers to provide education about MDS to physicians and patients, support for MDS research, patient support, and advocacy.

During the past decade, we have independently solicited funding for ten international symposia that have been attended by over 7,000 individuals—physicians and patients. These symposia are held biannually and have greatly improved our knowledge of these disorders as we continue to provide physicians worldwide with the most up-to-date information on research in MDS. The 10th International Symposium was held in Patras, Greece May 6–9, 2009.

What Does the Foundation Do?
The Foundation works to maintain an international information network to share new research and new treatment options as rapidly as possible, to provide information and educational support for both physicians and patients, and, ultimately, to provide funding and oversight for international studies of MDS. Currently the Foundation supplies patients, physicians, and other interested parties with information in the form of a quarterly newsletter, the MDS News, and The MDS Messenger, our e-newsletter. The Foundation’s website includes patient and physician information. Our web address is http://www.mds-foundation.org.

The Centers of Excellence Program designates institutions that meet the highest standards for diagnosis, treatment, and patient care. These Centers form the referral base for patients seeking first or second opinions and/or additional treatment options from experts in MDS. The Foundation provides patients with a priority referral to any Center of Excellence. Patient advocacy groups are being formed worldwide, and information is available that assists MDS patients and their loved ones in understanding these diseases and the treatment options that are available.

How Can You Help?
Funding for the Foundation comes from pharmaceutical companies, Foundation memberships, memorials, and donations from private individuals. While we have come a long way in the 15+ years since the Foundation was established we have a long way to go. Funding is the base for realizing the Foundation’s research and education goals.

The MDS Foundation is a publicly supported not-for-profit organization, exempt from federal income tax under section 501(c)(3) of the IRS code.

How Can We Help You?
Please do not hesitate to contact the Foundation if you have any questions.

MDS Headquarters:
4573 South Broad Street
Suite 150
Yardville, NJ 08620
Within the US: 1-800-MDS-0839
Outside the US: 609-298-1035
Fax: 609-298-0590
www.mds-foundation.org

...a survey indicated a very strong interest in, and a great need for, developing a permanent working group of scientists and patient advocates. Up until that time, no formal working group was devoted to these syndromes. The MDS Foundation was born.
THE 11TH INTERNATIONAL SYMPOSIUM ON MYELODYSPLASTIC SYNDROMES

EDINBURGH, UK, MAY 18 – 21, 2011

MDS 2011 will unite all professionals devoted to improving the quality of life of patients with Myelodysplastic Syndromes. World leaders will present the latest developments in the field in the hope of accelerating the process leading to the effective control and ultimate cure of these diseases – the mission of the MDS Foundation.

Combine your scientific interests with a chance to explore the enchanting city of EDINBURGH!

VIEW THE SCIENTIFIC PROGRAMME ONLINE & REGISTER NOW!

WWW.KENES.COM/MDS

MDS 2011 Symposium Secretariat c/o Kenes International
1-3 Rue de Chantepoulet, PO Box 1726, CH-1211 Geneva 1, Switzerland
Tel: + 41 22 906 0488; Fax: + 41 22 906 9140; E-mail: mds@kenes.com; © Kenes Group © 2010. All rights reserved.

For MDS Foundation Contact: US number: 1-800-MDS-0839, Outside the US: 1-609-298-1035
The MDS Foundation Says Regulatory Decision Approving Vidaza® In The Uk Provides An Essential Treatment Option To Patients

VIDAZA is the Only Licensed Drug Shown in Clinical Trials to Improve Survival

The Myelodysplastic Syndromes (MDS) Foundation — an international organization devoted to the prevention, treatment, and study of the myelodysplastic syndromes — today issued a statement applauding a decision from the National Institute for Health and Clinical Excellence in the UK (NICE) to recommend VIDAZA (azacitidine) in its approved indications for certain MDS patients.

MDS is a malignant bone marrow disease with a median survival of less than one year that can also progress to an aggressive form of leukemia called AML. VIDAZA from Celgene is the only drug approved by the EMA for MDS and is crucial to the treatment of this disease, especially for the majority of MDS patients, those over the age of 65 who are not eligible for bone marrow transplants. The NICE decision reverses a previous negative decision issued last year.

In 2009, data published in the peer-reviewed medical journal The Lancet Oncology confirmed that VIDAZA extends survival for patients with higher-risk MDS. In 2010 a study in a subset of these patients in the Journal of Clinical Oncology concluded VIDAZA “prolongs survival and is well tolerated” in higher risk MDS patients and those with acute myeloid leukemia (AML) with 20–30% marrow blasts (previously called RAEB-T in the FAB classification). The study found that half of the older patients (median age 70) treated with VIDAZA survived at least two years, compared to only 16% of patients who received conventional care.

VIDAZA is specifically approved for use in the treatment of intermediate-2 and high-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and the subset of AML patients indicated above who are not eligible for stem cell transplantation.

MDS Patients Achieve Access to Vital New Treatment Option

National Institute for Health and Clinical Excellence Recommend Azacitidine is Available Through the NHS

London (17 February 2011) – The National Institute for Health and Clinical Excellence (NICE) announced today that Vidaza (azacitidine), the only licensed drug available specifically to treat myelodysplastic syndromes (MDS) —a range of life-threatening bone marrow disorders— will be available through the NHS. The MDS UK Patient Support Group, which has been in consultation with NICE during the approval process and campaigned on behalf and in conjunction with MDS patients across the UK, welcomes this announcement.

There are nearly 3,000 new cases of MDS in the UK each year and many people newly diagnosed with MDS have not heard of this disorder before. A person with MDS will suffer from chronic tiredness and weakness due to the often extremely low levels of haemoglobin, owing to a malfunction in the bone marrow in producing the correct quantity and quality of blood cells. This is debilitating in itself and often requires regular blood transfusions.

Azacitidine is an anticancer drug that is thought to work by re-establishing cells’ natural mechanisms to control abnormal growth. The final appraisal determination by NICE recommends the use of azacitidine for the treatment of MDS, chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) following a revision to the patient access scheme provided by Celgene (the manufacturers of azacitidine). Rodney Taylor, Deputy Chairman of MDS UK Patient Support Group said, “I am delighted to hear of NICE’s decision to recommend azacitidine for these patient groups which can benefit from this form of treatment. Having been on azacitidine myself, I know how effective it can be in promoting a good quality of life, giving independence from blood transfusions and allowing patients to lead a normal family life. Azacitidine is the only specific treatment for MDS that improves quality of life, prolongs survival and delays disease progression. It is great news that many more patients will now be able to benefit from it.”

While the announcement is good news for MDS patients in England and Wales, MDS UK Patient Support Group is concerned that access to this vital new treatment is still denied to MDS patients in Scotland, as azacitidine has yet to be re-submitted to The Scottish Medicines Consortium (SMC) following a rejection in April 2010. We urge all concerned to apply both maximum effort and the highest priority to bring azacitidine to Scotland, in line with England and Wales.

“Clearly I am delighted that NICE has approved azacitidine for use in England and Wales in conjunction with the associated patient access scheme,” said Dominic Culligan, Consultant Haematologist, Aberdeen Royal Infirmary, Scotland. “I hope that Celgene will resubmit azacitidine to the SMC as a matter of urgency, so that further consideration can be given to making this important treatment for high risk MDS and some patients with AML available in Scotland.”
It is a distressing reality that, during the protracted evaluation process attendant to the successful outcome of this appraisal, some MDS patients have progressed to AML, and some did not survive, in the absence of azacitidine. MDS UK Patient Support Group are aware of the complex financial constraints and cost effectiveness criteria attendant to the adoption of new drugs, and ask only that even more effort is applied in reaching speedier positive conclusions in critical, end of life situations such as MDS.

**While there were very few options for MDS patients in the past, with the FDA approved therapies, patients are able to live a better quality of life...**

---

**ANNOUNCEMENT FROM MDS FOUNDATION**

**MDS Foundation Says ASH 2010 Highlights New Prognostic Capabilities and A Deeper Understanding of Treatment Options For This Once “Untreatable” Condition**

**Studies Explain Role of Genes in Susceptibility to MDS and Response to Treatment**

**Studies Confirm Benefits and Extend Potential of Existing Drugs and Drug Combinations, Including Oral Medications**

Yardville, NJ, Orlando, FL (Dec 3, 2010) – The Myelodysplastic Syndromes (MDS) Foundation today said significant advances are being made in understanding and treating MDS and a related condition, AML (acute myeloid leukemia). Key studies being presented this week include data on new markers and genetic mutations to predict susceptibility to MDS and response to treatment. Studies also look at new dosing and new combinations of existing drugs, and include an early look at new drug formulations showing increased potential and presenting more options for patients.

The new findings will be presented at the 52nd annual meeting of the American Society of Hematology (ASH), being held this week in Orlando, Florida.

MDS is a malignant condition of cells in the bone marrow. Patients require blood transfusions that can lead to iron overload, and the condition can progress to AML, a serious form of leukemia that has a median survival of less than one year. MDS affects the production and function of blood cells—red blood cells, white blood cells or platelets. The incidence of MDS and AML is underestimated, conservatively affecting tens of thousands of persons annually.

“These are challenging diseases that affect a growing number of persons each year with the graying of the US population; we are pleased to see the significant progress being made,” said Stephen D. Nimer, MD, Vice Chair, Faculty Development & Alfred P. Sloan Chair at Memorial Sloan-Kettering Cancer Center in New York and MDS Foundation board member. “While there were very few options for MDS patients in the past, with the FDA approved therapies, patients are able to live a better quality of life, often free from the time-consuming and tiring process of receiving frequent blood transfusions. It is encouraging to see additional confirmation that these new therapies are providing benefits for patients and that additional drugs are in development.”

Key MDS and AML studies to be presented at ASH include new ways to measure and determine susceptibility to MDS and predict response to treatment:
- data to validate the MD Anderson Risk Model (MDAS), a new, more accurate way to predict the natural history of a given patient’s disease to guide appropriate therapy (abstract #444, 12/6, 11:45 am)
- genetic markers to predict susceptibility to MDS (#LBA3, 12/7, 7:30 am and #612, 12/6, 4 pm)
- and a specific genetic mutation that may help predict response to treatment with VIDAZA® (azacitidine)#439, 12/6, 10:30 am)

Another key group of studies provide new data on treatment options for patients:
- a reduced dose and longer cycle of VIDAZA compared to the standard of treatment (50 mg vs 75 mg; 10 days vs 7 days) doubles the rate of hematologic normalization (#601, 12/6, 2:45 pm)
- an early look at a new regimen CPX-351, a liposome (encapsuled) formulation of cytarabine and daunorubicin in a specific ratio to maximize synergy, demonstrates higher response rate in newly diagnosed elderly patients with AML and in particular, AML that evolves from MDS (#655, 12/6, 4:30 pm)
- an oral version of the drug VIDAZA shows encouraging clinical responses in early testing (#603, 12/6, 3:15 pm)

Other studies found positive effects with combinations of drugs, such as REV/LIMID® (lenalidomide) plus intensive chemotherapy in elderly patients with higher-risk MDS and AML (#508, 12/6, 3:30 pm).

However, two studies dramatically show the need for a broader range of treatments, documenting a poor outcome for patients when current hypomethylator therapies fail and calling for clinical trials for this group of patients to take priority (#2913, 12/5, 6 pm; #443, 12/6, 11:30 am).

Alan List, MD, Physician-in-Chief at the Moffitt Cancer Center in Florida and board member of the MDS Foundation noted: “The growing ability to predict and assess disease incidence and outcome combined with a better understanding of current treatments makes this an important ASH conference for MDS patients and their physicians. Our arsenal is too small and we need more research, but we are encouraged by what we expect to see this year.”
Jacksonville Patient and Family Forum
Jacksonville, Florida • March 28, 2011

Guest speaker, Dr. Alvaro Moreno-Aspitia, Mayo Clinic.

Established MDS Patient Support Groups

UNITED STATES
- Chicago, Illinois Support Group meets on the fourth Tuesday of the month from 1:30–3:00 pm at Northwest Community Hospital’s Cancer Service department (lower level), 800 W. Central Road, Arlington Heights, Illinois. Contact Kim Jensen at kjensen@nch.org or call 847-618-6914.
- Puget Sound, Washington Support Group meets at the Seattle Cancer Care Alliance Center. Contact Steve Kessler at smartmony@msn.com or call: 800-877-0168.
- San Francisco Bay Area Support Group meets on the second Sunday of the month at 2 pm at the Park Blvd. Presbyterian Church, 4101 Park Blvd., Oakland, California. Contact 800-MDS-0839 for more information.
- Stanford Cancer Center MDS Patient & Family Support Group meets the 3rd Monday of the month, 6:30–8:00 pm at the Stanford Cancer Center, 875 Blake Wilbur Dr., Palo Alto, 2nd Floor Conference Room CC2105. Group Leader: Lenn Fechter, RN, BSN 650-725-0744.

CANADA
- Toronto, Ontario Support Group Contact William Pearson at william.pearson@sympatico.ca or call 905-561-6999 for information on upcoming meetings.

JAPAN
- Japanese Support Group Email: mdsrenraku@yahoo.co.jp for more information Website (only in Japanese): http://www.geocities.jp/mdsrenraku

EUROPE (Countryside Groups)
- France: Association Connaître et Combattre les Myélodyssplasies
- United Kingdom: UK MDS Patient Forum
- Czech Republic: Czech Republic MDS Forum
Los Angeles Patient and Family Forum
Beverly Hills, California • February 28, 2011

Nurse Erin Demakos, Mt. Sinai School of Medicine and member of the MDSF Nursing Advisory Board, moderates the quality-of-life session with patients and caregivers.

Dr. H. Phillip Koeffler from Cedars-Sinai Medical Center speaks to patients.

Air Transportation Options for Patients

Angels Donate Frequent Flyer Miles

The need for charitable airline tickets for patients traveling to distant specialized medical evaluation, diagnosis or treatment continues to grow.

During the previous year, programs administered by Mercy Medical Airlift provided almost 10,000 free airline tickets to financially-stressed patients, but many more were required. Unfortunately, resources to assist all were not available.

Help patients in need of distant transportation by donating Frequent Flyer Miles and make a difference in the life of a patient requiring distant specialized treatment. For further information go to http://www.donatefrequentflyermiles.org.

Angel Flight – For Those in Need

Air transportation resources may be available for patients considering travel to one of the participating sites that are part of the NIH Rare Diseases.

Angel Flight at NIH provides air transportation for patients who are in financial need and cannot afford the cost of air travel. The Angel Flight at NIH program is administered by Mercy Medical Airlift.

If you are interested in finding out if Angel Flight meets your air transportation needs, contact Marita Eddy at 301-451-9646 or email meddy@mail.nih.gov or check www.angelflightatnih.org.

---

Thank You to Our Pharmaceutical Supporters

We would like to thank our pharmaceutical supporters for their commitment to the Foundation and its work. They have contributed in the form of educational grants, which maintains not only this newsletter but also the development of the MDS homepage on the World Wide Web, the Center of Excellence program, continuing medical education programs, and the dissemination of patient information.
Spreading the Word Worldwide – Patient and Caregiver Education Forums

FREE One-Day Conferences for MDS Patients and Their Families

Ongoing meetings in the US and Europe addressing quality of life issues for MDS patients are planned for 2011. Learn the latest on the diagnosis and treatment of MDS from leading experts in the field. These conferences will occur in eleven cities around the world in 2011. A global patient forum will be held alongside the 11th International Symposium on MDS in Edinburgh, UK. Check our website and facebook for updates.

CALENDAR OF EVENTS:

- February 28, 2011
  Los Angeles, CA
- March 28, 2011
  Jacksonville, FL
- April 16, 2011
  Atlanta, GA
- May 20, 2011
  Edinburgh, United Kingdom
- May 26, 2011
  Baltimore, MD
- June 29, 2011
  San Antonio, TX
- July 9, 2011
  Seattle, WA
- Date TBD
  Chicago, Illinois
- Date TBD
  Nashville, Tennessee
- Date TBD
  Scottsdale, Arizona
- Date TBD
  Boston, Massachusetts

Please contact the MDS Foundation at 1-800-MDS-0839 for reservations/inquiries.

International Patient Support Groups – We Need Your Help!

The MDS Foundation is embarking on a very exciting project in 2011 – Patient Support Groups Worldwide!

Patient Support Groups are an excellent resource in assisting MDS patients and their caregivers. Those groups in existence have been vital to educating public awareness of this disease and promoting and supporting scientific research into the treatment and care of patients with MDS. Unfortunately, only a few such local groups exist, mostly in the US and the UK, and a few European countries. There is a pressing need to establish such groups worldwide.

Patient Support Groups have been vital to educating public awareness of this disease and promoting and supporting scientific research...

The Foundation has devoted selected members of its staff to establish and provide technical assistance to patient support groups outside of the United States in late 2010, with the goal of continuing this progress into 2011 and beyond.

By years end we will be reaching out to our International Centers of Excellence to request patient support needs specific to their geographical regions. International patient leaders and all healthcare professionals are also encouraged to forward patient support needs, specific to you and/or your geographical region, to the Foundation at patientliaison@mds-foundation.org or 609-298-1035. We look forward to hearing from you!

Please let us know – we will help!

The MDS Foundation Needs Your Help!

For individuals and families affected by MDS, it’s more important than ever to raise funds for the Foundation in 2011.

For the past 15 years, The MDS Foundation (MDSF) has provided services to patients, their families, and healthcare providers working in the field.

With changes in regulations and restrictions on corporate support, we need your support more than ever this year to continue producing these vital programs.

For the first time, MDSF donors can dedicate the use of their contributions to one of the critical services we provide.

- PATIENT ADVOCACY
  Patient forums, support groups, information requests, referrals

- RESEARCH
  Clinical trial assistance, physician advisory boards, international working groups on cytogenetics, morphology, diagnostics, quality of life

- HEALTHCARE PROVIDER EDUCATION
  International physician and nursing symposia, interactive/web-based continuing education initiatives, abstracts & manuscripts

Kindly use the enclosed donation envelope or go to:

www.mds-foundation.org to donate today.

Thank you for your continued support!
Fundraising Cookbook to Benefit MDS

Nancy Cosenza Nussbaum

November 21st is a day that will always sadden my heart and burden my soul as it is the day that my sister, Ann Cosenza Hallberg, left this life, as we know it.

Ann was diagnosed with MDS early 2009; our brother, Alan, was a perfect match for her stem cell transplant which took place in June 2009, with all markers at the optimum readings. Her prognosis was good. We figured the rest of 2009 would be spent watching her getting stronger and getting well. There were plans for 2010, though. Ann’s son, Rob, was graduating from high school and a family trip would have been in order early summer. Ann wanted to see him settled in his dorm in fall, 2010 and she and I were going to spend a week in New York. Dinners, shopping, and theater... you name it... it was on our agenda. She talked with her husband, Steve about a romantic holiday to Paris. Their 20th wedding anniversary would have been in May, 2010 and she wanted everyone to go to a certain restaurant in NY that she loved where we would all celebrate.

Having been trained in the arts, Ann had a career change in mind for when she was well, and that was to work with MDS patients. She had already spoken with her doctor about starting a support group at Yale for people awaiting transplants and support for thereafter.

2010 was going to be a wonderful year of love, celebration of life and service.

But, what happened was that while the stem cell transplant was successful, graft versus host disease set in and took our beloved sister, wife, mother, daughter, aunt and niece from us. We watched her slowly fading from us, always with the hope that she was reacting poorly to meds and once off them, she would bounce back. Unfortunately, it was not to be.

Ann left us on November 21, 2009 at 9:45 pm.

How this has affected our family has been heart wrenching. As each of us had our own special relationship with Ann, our expressions of loss are all very different.

Right after we lost her, I felt the need to do something immediately to honor her and keep her with me so The Ann Cosenza Hallberg Toy Drive was established and we collected multiple cartons of new toys for the hospital’s Toy Closet for the young patients.

There was communication with Audrey Hassan with the MDS Foundation about fund raising ideas. The idea of a walk was mentioned, but I was already planning a walk for the Connecticut Food Bank and our team name, of course, was Team Ann Hallberg.

In the interim, our sister, Christine set up a memorial fund in Ann’s name with MDS for research. I was still trying to figure out what I could do for MDS Foundation... and one evening it just came to me... a cookbook! I talked it over with my family and decided we would publish a cookbook with recipes from family and friends, local restaurants in the greater New Haven area and some well known bakers and chefs. All profits will go to Ann Cosenza Hallberg Memorial Fund with MDS Foundation for research to help eradicate the disease and complications.

At this time, the recipes have been collected and we await the finished cookbooks from the publisher. They are $10 each and 100% of this money will be donated to the MDS Foundation. We are also requesting $3.00 for shipping & handling. For further information please email me at AnniesSweetTooth@gmail.com. Please also check out www.anniessweettooth.blogspot.com as we continue sharing recipes and food talk.

So, for me, continuing charitable work in my sister’s name keeps her with me and allows others to know her and become aware of MDS.

For Ann...

i carry your heart

...i carry your heart with me (i carry it in my heart) i am never without it (anywhere i go you go, my dear; and whatever is done by only me is your doing)...)

...here is the deepest secret nobody knows (here is the root of the root and the bud of the bud and the sky of the sky of a tree called life; which grows higher than soul can hope or mind can hide) and this is the wonder that’s keeping the stars apart

i carry your heart (i carry it in my heart)

– e.e. cummings
Family Fun for Fundraising Ideas
A to Z...

We try to make your fundraising efforts a little easier by providing a wide variety of fundraising ideas. One of them may be perfect for your next fundraiser!

Auction • Arts and crafts sale • Autograph sale...

Blood/bone marrow drive • Bike-a-thon Bake sale • Book sale • Benefit concert or party • Band/Choir Fundraiser • Barbecue • Bridge tournament • Bowling • Bingo...

Cake bake • Candy Fundraiser • Car wash • Celebrity auction • Church fundraiser • Collection boxes • Cookbook (produce a community cookbook that you can sell) • Calendar production and sale • Cheese and wine evening • Cheerleader fundraiser • Christmas cards...

Dinner dance/ball • Darts tournament...

eBay (register and auction off your old, unwanted items) • Eating contest • Easter party (easter egg hunt, easter egg auction, etc.)...

Fundraising night out at a local restaurant Fairs • Face painting • Fashion show • Flower/fruit sales • Foreign coins collection • Fun run...

Galas • Game night • Golf tournament Garage/yard/estate sale • Greeting cards...

Home fundraising party (Tupperware, PartyLite, Pampered Chef, Silpada, etc.) House Party • Halloween Party...

Individual gifts (pledges, an hour’s pay, donations, membership, payroll giving, etc.) • Ice-skating • Ice cream social...

Jog-a-thon • Jewelry sale • Judo competition or demonstration...

Karaoke night/competition • Kite flying Knitting...

Lawn mowing • Luncheon...

Marathons • Musicals • Murder mystery dinner/event • Movie premiere...

New Year’s Eve party • Netball match...

Old gold (send us your old and broken jewelry or bring it to a Cash for Gold jewelry store and donate the proceeds) Obstacle course • Opera night...

Pancake breakfast • Parties (birthday, anniversary, etc.) • Plant sale • Poker/blackjack/backgammon/bridge tournament • Picnics • PTA fundraiser...

Quiz night...

Run/Walk/Hike/Bike • Raffles • Read-a-thon • Recipe sales...

Spaghetti Dinner fundraiser • School fundraiser • Silent/live/online auction • Sports tournaments (soccer, golf, basketball, bowling, etc.) • Super Bowl party • Scavenger hunt • School fair • Sorority fundraiser...

Triathlon • Talent show • Tea party • Treasure hunt • Tennis tournament...

University activities/fundraisers...

Volleyball tournament • Vendor fair • Valentine’s ball...

Wacky races • Wine/food tasting...

Xmas stocking bazaar • Xmas cake sale Xmas card donation...

Youth group fundraiser • Yoga marathon Yacht race • Yo-yo competition...

Zany parties • Zoo trips • Zodiac readings...

CAN YOU COME UP WITH MORE?
If you have some fundraising ideas that you are willing to make available, send them to us via email at patientliaison@mds-foundation.org and we will include them in this section.

The MDS Foundation is very grateful for the heartfelt support of its donors. Our work as a non-profit organization depends on public funding...

FREE...
Patient Resource Cancer Guide

Patient Resource Cancer Guide was created to empower and prepare newly diagnosed and newly restaged cancer patients to become their own advocates.

Go to PatientResource.net to order your complimentary copy today or call (816) 333-3595, ext. 26.
Would you like your treatment center to become part of the referral system for MDS patients and be designated as a Center of Excellence? To be recognized as a Center of Excellence, an institution must have the following:

- An established university (or equivalent) program
- Recognized morphologic expertise in MDS
- Available cytogenetics and/or molecular genetics
- Ongoing research, including Institutional Review
- Board–approved clinical trials
- Documentation of peer-reviewed publications in the field
- The ability and intention to register patients in the MDS International Registry database

Please contact the Foundation for further information and an application form for your center.

The following centers have qualified as MDS Centers of Excellence:

### UNITED STATES

#### ARIZONA
- Mayo Clinic Hospital
  - Phoenix, Arizona
  - Ruben Mesa, MD; James Slack, MD
- University of Arizona
  - Arizona Cancer Center
  - Tucson, Arizona
  - Daruka Mahadevan, MD, PhD

#### CALIFORNIA
- Cedars-Sinai Medical Center
  - Los Angeles, California
  - H. Phillip Koehler, MD
- City of Hope National Medical Center
  - Duarte, California
  - Stephen J. Forman, MD
- Stanford University Medical Center
  - Stanford, California
  - Peter L. Greenberg, MD
- UCLA Center for Health Science
  - Los Angeles, California
  - Gary J. Schiller, MD
- University of Southern California
  - Keck School of Medicine
  - Los Angeles, California
  - Casey L. O’Connell, MD

#### FLORIDA
- All Children’s Hospital
  - St. Petersburg, Florida
  - Gregory Hale, MD
- Mayo Clinic
  - Jacksonville, Florida
  - Alvaro Moreno-Aspitia, MD
- University of Florida Shands Hospital
  - Gainesville, Florida
  - Christopher R. Cogle, MD
- University of South Florida
  - H. Lee Moffitt Cancer Center and Research Institute
  - Tampa, Florida
  - Alan F. List, MD

#### GEORGIA
- Emory Winship Cancer Institute
  - Atlanta, Georgia
  - Amelia Langston, MD
- Emory University School of Medicine
  - Atlanta, Georgia
  - Amelia Langston, MD

#### ILLINOIS
- Loyola University Chicago
  - Cardinal Bernardin Cancer Center
  - Maywood, Illinois
  - Scott E. Smith, MD, PhD
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University
  - Feinberg School of Medicine
  - Chicago, Illinois
  - Olga Frankl
- Rush University Medical Center
  - Chicago, Illinois
  - Stephanie Gregory, MD
  - Jamiel Shammo, MD
- University of Chicago Medical Center
  - Chicago, Illinois
  - Richard A. Larson, MD

#### INDIANA
- Indiana University Medical Center
  - Indianapolis, Indiana
  - Larry Crise, MD

#### MARYLAND
- Johns Hopkins University School of Medicine
  - Baltimore, Maryland
  - Steven D. Gore, MD
  - Charles S. Hesdorffer, MD
- University of Maryland Greenebaum Cancer Center
  - Baltimore, Maryland
  - Maria R. Baer, MD
  - Ivana Gojo, MD

#### MASSACHUSETTS
- Dana-Farber Cancer Institute
  - Boston, Massachusetts
  - David P. Steensma, MD
  - Richard M. Stone, MD
- Tufts University School of Medicine
  - Tufts Medical Center
  - Boston, Massachusetts
  - Kellie Sprague, MD

#### MICHIGAN
- Barbara Ann Karmanos Cancer Institute
  - Wayne State University
  - Detroit, Michigan
  - Charles A. Schiffer, MD
- William Beaumont Hospital
  - Cancer Center
  - Royal Oak, Michigan
  - Inma Jaisesim, MD

#### MINNESOTA
- Mayo Clinic
  - Rochester, Minnesota
  - Mark R. Litzow, MD
- University of Minnesota Medical Center
  - Fairview University of Minnesota Medical School
  - Minneapolis, Minnesota
  - Erica D. Warlick, MD

#### MISSOURI
- Washington University School of Medicine
  - Siteman Cancer Center
  - St. Louis, Missouri
  - John F. DiPersio, MD, PhD

#### NEBRASKA
- University of Nebraska Medical Center
  - Omaha, Nebraska
  - Lori Maness, MD

#### NEW JERSEY
- The Cancer Center of Hackensack University Medical Center
  - Hackensack, New Jersey
  - Stuart Goldberg, MD

#### NEW YORK
- Albert Einstein College of Medicine Cancer Center
  - Bronx, New York
  - Amit Verna, MD
- Columbia University Medical Center
  - New York, New York
  - Azra Razza, MD
- Memorial Sloan-Kettering Cancer Center
  - New York, New York
  - Stephen D. Nimer, MD
- Mount Sinai School of Medicine
  - New York, New York
  - Lewis R. Silberman, MD
- New York Medical College/ Westchester Medical Center
  - Valhalla, New York
  - Karen Seiter, MD

#### NORTH CAROLINA
- Duke University Medical Center
  - Durham, North Carolina
  - Carlos M. deCastro, MD
- Wake Forest University School of Medicine
  - Comprehensive Cancer Center
  - Winston-Salem, North Carolina
  - Bayard L. Powell, MD

#### OHIO
- Cleveland Clinic Foundation
  - Taussig Cancer Center
  - Cleveland, Ohio
  - Jaroslaw Maciejewski, MD, PhD

#### PENNSYLVANIA
- The Western Pennsylvania Cancer Institute
  - Pittsburgh, Pennsylvania
  - James M. Rossetti, DO
<table>
<thead>
<tr>
<th>Country</th>
<th>Institutions and Departments</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFRICA</td>
<td>Hôpital Aziza Othmana, Tunis, Tunisia</td>
</tr>
<tr>
<td></td>
<td>Baikis Meddeb, MD</td>
</tr>
<tr>
<td></td>
<td>University of Cape Town Grote Schuur Hospital, Cape Town, South Africa</td>
</tr>
<tr>
<td></td>
<td>Nicolás Novitzky, MD</td>
</tr>
<tr>
<td></td>
<td>Sanatorio Guemes, Buenos Aires University</td>
</tr>
<tr>
<td></td>
<td>Marcelo Iastrebn, MD</td>
</tr>
<tr>
<td></td>
<td>Royal Hobart Hospital HOBART, TASMANIA, AUSTRALIA, AUSTRALIA</td>
</tr>
<tr>
<td></td>
<td>Raymond M. Lowenthal, MD</td>
</tr>
<tr>
<td></td>
<td>University Hospital of Innsbruck, Innsbruck, Austria</td>
</tr>
<tr>
<td></td>
<td>Reinhard Stauder, MD</td>
</tr>
<tr>
<td></td>
<td>University of Vienna Vienna, Austria</td>
</tr>
<tr>
<td></td>
<td>Peter Valent, MD</td>
</tr>
<tr>
<td></td>
<td>AZ Sint-Jan AV, Brugge, Belgium</td>
</tr>
<tr>
<td></td>
<td>Dominik Sellelag, MD</td>
</tr>
<tr>
<td></td>
<td>University Hospital Leuven, Leuven, Belgium</td>
</tr>
<tr>
<td></td>
<td>Michel Delforge, MD</td>
</tr>
<tr>
<td></td>
<td>AC Camargo Hospital – Cancer Center São Paulo, Brazil</td>
</tr>
<tr>
<td></td>
<td>Luiz Fernando Lopes, MD</td>
</tr>
<tr>
<td></td>
<td>Hemocentro da UNICAMP University of Campinas, Campinas, Brazil</td>
</tr>
<tr>
<td></td>
<td>Irene Lorand-Metze, MD</td>
</tr>
<tr>
<td></td>
<td>Servicio de Hematologia do Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo</td>
</tr>
<tr>
<td></td>
<td>Silvia Maria M. Magalhães, MD</td>
</tr>
<tr>
<td></td>
<td>Universidade Federal de Ceará Ceará, Brazil</td>
</tr>
<tr>
<td></td>
<td>Maria de Lourdes Chauffaille, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Princess Margaret Hospital Toronto, Ontario, Canada</td>
</tr>
<tr>
<td></td>
<td>Karen Yee, MD</td>
</tr>
<tr>
<td></td>
<td>Toronto Sunnybrook Regional Cancer Centre Toronto, Ontario, Canada</td>
</tr>
<tr>
<td></td>
<td>Richard A. Wells, MD</td>
</tr>
<tr>
<td></td>
<td>University of Toronto Hospital for Sick Children Toronto, Ontario, Canada</td>
</tr>
<tr>
<td></td>
<td>Yigal Droz, MD</td>
</tr>
<tr>
<td></td>
<td>Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences Tianjin, China</td>
</tr>
<tr>
<td></td>
<td>Zhijian Xiao, MD</td>
</tr>
<tr>
<td></td>
<td>University Hospital Center Zagreb School of Medicine Zagreb, Croatia</td>
</tr>
<tr>
<td></td>
<td>Boris Labar, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Ranka Sertvent-Seiwert, MD</td>
</tr>
<tr>
<td></td>
<td>Institute of Hematology &amp; Blood Transfusion Prague, Czech Republic</td>
</tr>
<tr>
<td></td>
<td>Jaroslav Cermák, MD</td>
</tr>
<tr>
<td></td>
<td>Odense University Hospital The University of Southern Denmark</td>
</tr>
<tr>
<td></td>
<td>Gitte Birk Kershoup, MD</td>
</tr>
<tr>
<td></td>
<td>Rigshospitalet National University Hospital Copenhagen, Denmark</td>
</tr>
<tr>
<td></td>
<td>Lars Kjeldsen, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>University of Århus The University Hospital Århus, Denmark</td>
</tr>
<tr>
<td></td>
<td>Mette Selov Holm, MD</td>
</tr>
<tr>
<td></td>
<td>Centre Henri Becquerel Rouen University School of Medicine Rouen, France</td>
</tr>
<tr>
<td></td>
<td>Aspasia Stamatooulos, MD</td>
</tr>
<tr>
<td></td>
<td>Centre Hospitalier Universitaire (CHU) de Angers Service des Maladies du Sang Angers, France</td>
</tr>
<tr>
<td></td>
<td>Norbert Ifrah, MD</td>
</tr>
<tr>
<td></td>
<td>Centre Hospitalier Universitaire (CHU) de Grenoble Grenoble, France</td>
</tr>
<tr>
<td></td>
<td>Jean-Yves Cahn, MD</td>
</tr>
<tr>
<td></td>
<td>Hôpital Claude Huriez, CHU Lille Service des Maladies du Sang Lille, France</td>
</tr>
<tr>
<td></td>
<td>Bruno Queineel, MD</td>
</tr>
<tr>
<td></td>
<td>Hôpital Cochin/University Paris V Paris, France</td>
</tr>
<tr>
<td></td>
<td>Francois Dreyfus, MD</td>
</tr>
<tr>
<td></td>
<td>Hôpital Saint Louis/University Paris VII Paris, France</td>
</tr>
<tr>
<td></td>
<td>Christine Chomienne, MD</td>
</tr>
<tr>
<td></td>
<td>Institut Paoli-Calmettes Marseille, France</td>
</tr>
<tr>
<td></td>
<td>Norbert Vey, MD</td>
</tr>
<tr>
<td></td>
<td>Georg-August-Universität Göttingen, Germany</td>
</tr>
<tr>
<td></td>
<td>Detlef Haase, MD, PhD</td>
</tr>
<tr>
<td></td>
<td>Hannover Medical School Medizinische Hochschule Hannover Hannover, Germany</td>
</tr>
<tr>
<td></td>
<td>Arnold Ganser, MD</td>
</tr>
<tr>
<td></td>
<td>Heinrich-Heine Universität Düsseldorf University Hospital Düsseldorf, Germany</td>
</tr>
<tr>
<td></td>
<td>Ulrich Germing, MD</td>
</tr>
<tr>
<td></td>
<td>Johann Wolfgang Goethe Universität Frankfurt Main, Germany</td>
</tr>
<tr>
<td></td>
<td>Gesine Bug, MD</td>
</tr>
<tr>
<td></td>
<td>Klinikum Rechts der Isar Technical University of Munich Munich, Germany</td>
</tr>
<tr>
<td></td>
<td>Katharina Götz, MD</td>
</tr>
<tr>
<td></td>
<td>MLL Münchner Leukämiebad Munich, Germany</td>
</tr>
<tr>
<td></td>
<td>Torsten Haferlach, MD</td>
</tr>
<tr>
<td></td>
<td>Saarland University Medical Center Homburg/Saar, Germany</td>
</tr>
<tr>
<td></td>
<td>Ulrich Mahknecht, MD</td>
</tr>
</tbody>
</table>
Discussions in Therapy

Management of Iron Overload in MDS

Peter L. Greenberg, MD
Stanford University Cancer Center and Professor of Medicine/Hematology
Stanford University School of Medicine
Palo Alto, California

Red blood cell (RBC) transfusions are a major component of the supportive care for symptomatically anemic MDS patients. Although the specific therapies patients receive may alleviate RBC transfusion need, a substantial proportion of MDS patients may not respond to these treatments and may develop iron overload as well as its consequences.1

Studies in patients requiring relatively large numbers of RBC transfusions (e.g., thalassemia and MDS) have demonstrated the pathophysiology and adverse effects of chronic iron overload on hepatic, cardiac and endocrine function. Increased nontransferrin bound iron (NTBI) levels, generated when plasma iron exceeds transferrin’s binding capacity, combines with oxygen to form hydroxyl and oxygen radicals. These toxic elements cause lipid peroxidation and cell membrane, protein, DNA and organ damage.2

Retrospective evidence suggests that organ dysfunction may result from iron overload in patients with MDS and that transfusional iron overload might be a contributor to increased mortality and morbidity in early stage MDS.3,4 The WPSS has shown that requirement for RBC transfusions is a negative prognostic factor for patients with MDS.4

For patients with chronic RBC transfusion need, serum ferritin levels, number of RBC transfusions received and associated organ dysfunction (heart, liver, and pancreas) should be monitored to determine iron stores. Monitoring serum ferritin may be useful, aiming to decrease ferritin levels to <1,000 mcg/L. Such measurements, though useful, are less precise than use of specific measurement of hepatic (and more recently cardiac) magnetic resonance imaging (MRI) evaluations of hepatic iron content.5

The current clinical availability of two iron chelators in the U.S., deferoxamine (Desferal) for subcutaneous (SC) or IV use and deferasirox (Exjade) for oral use, now provides potentially useful drugs for treating this iron overload state. A third chelating agent, available in Europe, deferiprone for oral use is not available in the US.

Clinical trials in MDS are ongoing with iron chelating agents to address the question whether iron chelation alters the natural history of patients with MDS who are transfusion dependent. Reversal of some of the consequences of iron overload in MDS and other iron overload states (e.g., thalassemia) by iron chelation therapy using deferasirox orally6 and deferoxamine subcutaneously (SC)7 have been shown. Such findings have potential implications for altering the morbidity of MDS patients, particularly those with preexisting cardiac or hepatic dysfunction. A recent U.S. National Comprehensive Cancer Network (NCCN) task force report discusses in detail the available evidence regarding iron chelation in patients with MDS.8

Based on the available, but limited evidence, both the MDS Foundation (mds-foundation.org), and the NCCN MDS Guidelines Panel, have recommended that chelation therapy be considered to decrease iron overload in selected MDS patients. Deferasirox 20 mg/kg orally once daily or deferoxamine 8 hrs SC infusion nightly 5–7 nights per week, are acceptable alternatives for low or intermediate1 MDS patients who have received or are anticipated to receive greater than 20 RBC transfusions, for whom ongoing RBC transfusions are anticipated and for those with serum ferritin >2500 ng/mL, aiming to decrease ferritin levels to <1,000 ng/mL.9 In addition, evidence suggests the potential value of iron chelation in patients who subsequently undergo allogeneic hematopoietic stem cell transplantation.9

Although deferasirox is generally well tolerated other than episodes of gastro-intestinal distress and renal dysfunction in some patients, recently a safety warning by the FDA and Novartis was added to deferasirox treatment guidelines. Following post-marketing use of deferasirox, there were rare case reports of acute renal failure or hepatic failure, some with a fatal outcome. Additionally, there were post-marketing reports of cytopenias, including agranulocytosis, neutropenia and thrombocytopenia and GI bleeding in patients treated with deferasirox. The relationship of these episodes to treatment with deferasirox has not yet been established. However, it is recommended to closely monitor patients on deferasirox therapy including measurement of serum creatinine and liver function tests prior to initiation of therapy and regularly thereafter.

Currently, a large international Phase III clinical is ongoing comparing treatment of deferasirox to placebo, which should help establish the clinical value of deferasirox in iron-overloaded MDS patients.

References:

New Research Protocol Listing

NATIONAL CANCER INSTITUTE TRIALS

As we go to press the National Cancer Institute (NCI) has listed more than 100 clinical trials that focus on myelodysplastic syndromes. Full study information on these trials is available at www.cancer.gov. This information includes basic study information, study lead organizations, study sites, and contact information. To access the information:

- Log on to www.cancer.gov
- Click on “Search for Clinical Trials”
- Click on “Type of Cancer” and type in ‘myelodysplastic syndromes’
- Hit search

This search will provide you with all the trials currently underway in MDS. You may also sort by trials that only focus on treatment or trials that only focus on supportive care.

To view listings of additional studies you can log onto www.clinicaltrials.gov. For telephone support, call the National Cancer Institute at 1-800-4-CANCER.

Clinical Research Trial with Eltrombopag – Now Open for Accrual

PMA112509

We would like to announce a clinical trial for patients with advanced Myelodysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS (sAML/MDS), or de novo AML who have associated thrombocytopenia (low platelet counts).

The Myelodysplastic Syndromes Foundation is assisting in the accrual of patients for Clinical Trial PMA112509. The purpose of this phase I/II placebo-controlled study is to test the safety of eltrombopag in patients with low platelet counts due to MDS, sAML/MDS, or de novo AML, and also to see how well eltrombopag may work at different doses in this patient population.

Eltrombopag is an orally available, small molecule thrombopoietin receptor agonist that is approved as a treatment for chronic immune (idiopathic) thrombocytopenic purpura (ITP) to increase platelet counts. The present study is designed to evaluate the safety and tolerability of eltrombopag, administered as oral tablets once daily in adult thrombocytopenic subjects with advanced MDS, sAML/MDS, or de novo AML.

In an effort to move the clinical development of eltrombopag for the treatment of MDS, sAML/MDS, or de novo AML forward as rapidly as possible, the Foundation would appreciate hearing from you.

If you are a physician and would like to refer a patient for enrollment into this clinical trial or if you are an MDS patient who has low platelet counts, please contact The MDS Foundation at 1-800-MDS-0839.

PMA112509 CLINICAL TRIAL SITE LIST (at date of publication)

UNITED STATES

Abrahamson Cancer Center of the University of Pennsylvania
Philadelphia, PA
Noelle Frey, MD

Albert Einstein Cancer Center at the Montefiore Medical Park
Bronx, NY
Amit Verma, MD

Arlington Fairfax Hematology Oncology
Arlington, VA
John Feigert, MD

Bon Secours Saint Francis Hospital
Greenville, SC
Gary Spitzer, MD

Cancer Care Centers of South Texas
New Braunfels, TX
Roger Lyons, MD

Cancer Care Centers of South Texas
San Antonio, TX
Roger Lyons, MD

Cooper Cancer Institute
Camden, NJ
Neil Lachant, MD

Fairfax Northern Virginia Hematology Oncology
Fairfax, VA
John Feigert, MD

Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD
Steven Gore, MD

Medical Specialists of the Palm Beaches
FLORA Research Associates
Lake Worth, FL
Gracy Joshua, MD

Stanford University Cancer Center
Stanford, CA
Peter Greenberg, MD

Tufts Medical Center
Boston, MA
Kenneth Miller, MD

Veteran Affairs Medical Center
Kansas City, MO
Suman Kambhampati, MD

Washington University School of Medicine
St. Louis, MO
Camille Abboud, MD

The West Clinic
Memphis, TN
Bradley Somer, MD

New Research Protocol Listings

The MDS Foundation wants you to know about clinical trials of investigational treatment options for patients with MDS and has updated its International Clinical Trials list on our website and for distribution. Please contact us for a detailed listing featuring new protocols:

Website: www.mds-foundation.org
Email: patientliaison@mds-foundation.org
or call 800-MDS-0839 and the current clinical trials will be sent to you.

Clinical trials often have very specific eligibility requirements. Please talk with your doctor to help decide which, if any, trials might be right for you.

Please note that the information is provided strictly as a resource and is not an endorsement of any physician, institution, or treatment.
**Announcing New Clinical Trials**

**NAME OF INSTITUTION:** Novartis Pharmaceuticals  
**TRIAL NUMBER:** NCT01241500  
**Title of Trial or Description:**  
**A Phase III Study of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients Who Have Failed or Relapsed After Azacitidine or Decitabine Treatment (ONTIME)**  
Currently Recruiting Participants.

The primary purpose of this study is to compare overall survival (OS) in patients receiving ON 01910.Na infusion administered every other week + best supportive care (BSC) to OS of patients receiving BSC in a population of patients with MDS with excess blasts (5% to 30% bone marrow blasts) having failed, being intolerant, or relapsing after azacitidine or decitabine treatment.

Contact the Onconova Clinical Trials Hotline at 1.855.609.6564 toll free or go to www.clinicaltrials.gov for additional information.

**NAME OF INSTITUTION:** Novartis Pharmaceuticals  
**TRIAL NUMBER:** NCT00940602  
**Title of Trial or Description:**  
**Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study (TELESTO)**  
A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial of Deferasirox in Patients With Myelodysplastic Syndromes (Low/Int-1 Risk) and Transfusional Iron Overload

Currently Recruiting Participants.

The primary purpose of this study is to prospectively assess the efficacy and safety of iron chelation therapy with deferasirox compared to placebo in patients with myelodysplastic syndromes (low/Int-1 risk) and transfusional iron overload.

Contact the Novartis Clinical Trials Hotline at 800-340-6843 or go to www.clinicaltrials.gov for additional information and to view the active sites.

**NAME OF INSTITUTION:** Celgene Corporation  
**TRIAL NUMBER:** NCT01029262  
**Title of Trial or Description:**  
**A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q (MDS-005)**  
Currently Recruiting Participants.

The primary purpose of this study is to compare the efficacy of Lenalidomide (Revlimid®) versus placebo in achieving red blood cell transfusion independence in the overall study population and in a pre-specified subgroup of patients with an erythroid differentiation gene expression signature predictive of Lenalidomide response.


---

**Online Search Tool for Clinical Trials**

**TrialCheck**  
Clinical trials information and products powered by:  
Coalition of Cancer Cooperative Groups

TrialCheck is another online search tool that helps you gather information about cancer clinical trials to discuss with your doctor. This user-friendly tool allows you to search for trials according to your type of cancer and according to your zip code. This will help you locate physicians and hospitals near your home that offer trials.

TrialCheck searching is based on nine simple questions. Depending upon the answers you provide, TrialCheck generates a list of trials in which you may be eligible to enroll.

**Educational Resources**

**Highlights of Latest Literature in MDS**

**Suneel D. Mundle, PhD**

Listed below are citations of some new publications relevant to MDS (pathogenesis, clinical characterization, management, etc.). To access the complete article log on to www.pubmed.gov.

**Epidemiology:**


   Compared to non-smokers, the patients who smoked at the initial clinical encounter had an increased risk of death particularly among the low-risk IPSS category. Interestingly, the smoking related risk was restricted only to men.


   A comprehensive update review of epidemiology, diagnosis and management of MDS.


   Of the 190 participants in this single center study, 35% had unexplained anemia with concomitant mild increase in inflammatory markers. The unexplained anemia patients also demonstrated correlating low Hb and low erythropoietin levels. Sixteen percent were suspicious MDS.

**Treatment:**

**Growth Factors:**


   This is a single arm, open-label, multicenter, phase II study that evaluated efficacy and safety of a weekly 300 µg dose of darbepoetin alfa in a well-selected low-/intermediate-1 risk MDS population with Hg<10 g/dL, endogenous EPO levels <500 IU/L and transfusions <2 units/month. For patients not showing major response to darbepoetin alfa in 8 weeks, filgrastim was added at 300 µg/week. Majority of major erythroid responses (31/44 or 71%) were evident after week 8 with only one additional response at week 24. Darbepoetin was well tolerated.


   A combination of Horse ATG 15 mg/kg and oral cyclosporine was assessed (n=45) with or without best supportive care (n=43). The primary endpoint was hematopoietic response at 6 months. The hematopoietic response rates after 6 months of treatment were significantly higher with ATG+ cyclosporine (13/45, p=0.0156) as compared to the best supportive care alone (4/43). However, no difference was noted in transformation free survival or the overall survival between the two groups.

**IMiDs:**


   A small study with 37 MDS patients treated with a combination of cyclosporin A and thalidomide demonstrated hematologic improvement in 51.4% patients and transfusion independence in 46.9% patients. The treatment was well tolerated and the responses were durable.

**Demethylating Agents:**


   This study undertook secondary analysis of the phase III AZA-001 study that used 75 mg/m²/day sc for days 1–7 every 28 days. Ninety one of 179 patients in AZA-001 had demonstrated response with 91% of the first responses occurring by cycle 6. The present study showed that continued azacitidine improved response category in 48% of these responders with a median time from the first response to best response being 3.5 cycles.

**Pathobiology:**


   A high CD34 expression was detected on mature looking megakaryocytes in 14% bone marrows of the total of 202 MDS patients assessed. The elevated CD34 expression was correlated with severe cytopenia, higher number of myeloblasts, higher cytogenetic abnormalities and poorer overall survival.


   Lenalidomide may suppress a haplodeficient phosphatase PP2A activity in 5q- patients, which by way of hyperphosphorylating and stabilizing MDM2 may allow p53 degradation, cause G2 arrest and lead to a clonal suppression.


   A combined karyotyping with metaphase cytogenetics(MC) and single nucleotide polymorphism (SNP) array demonstrated higher detectability of cytogenetic abnormalities than the MC alone (74 vs. 44%, p<0.0001). This analysis with 430 patients also revealed that SNP array-detected abnormalities may have independent predictability for overall and event-free survival.


   MDS patients’ CD34+ cells were injected along with human mesenchymal stem cells into the bone marrow of SCID/IL2gammaR null host mice. A successful engraftment of MDS CD34+ cells was seen with a maintenance of immunophenotype, genomic abnormalities and trilineage differentiation of the patients’ CD34+ cells. Two AML samples demonstrated leukemic clone engraftment and expansion.


   The study reports on decreased expression of SMAD7; a negative regulator of TGF-beta receptor I kinase, in MDS-derived bone marrow CD34+ cells. Furthermore, the study also demonstrated that LY-2157199, an ALK-5 kinase inhibitor, could inhibit TGF-beta signaling as indicated by inhibition of downstream SMAD2 activation. This kinase inhibitor when administered in vivo, ameliorated anemia in a TGF-beta overexpressing transgenic mouse model of bone marrow failure.

We would like to thank Suneel Mundle, a member of the MDS Foundation, for his assistance in monitoring these important peer-review publications on MDS.
Thank You!

Gifts to the Foundation

The MDS Foundation relies entirely on gifts and membership fees to further its work. We would like to acknowledge the generosity of the following individuals and organizations that have recently provided gifts to the Foundation:

- Susan J. Ferber, in memory of Dr. Jerome Ferber, New York, NY
- Donna S. Wolfe, New York, NY
- Alvin & Rosa Hudgins, University Park, FL
- Theresa Johnson, Leonardtown, MD
- Jeannette Shaffner, Yuba City, CA
- Steve Glass, Tallahassee, FL
- Vernetta E. Godfrey, Capitola, CA
- Sidney Schwartz, Los Angeles, CA
- William M. Pearson, Ontario, Canada
- Mario Cazzola, Pavia, Italy
- Joan F.D. Latsko, Pittsburgh, PA
- Lenn Fechter, San Carlos, CA
- Martina Wiedmayer, Collegeville, PA
- Paul M. Nemiroff, Gibsonia, PA
- Myrna H. James, Hemet, CA
- Teresa Anson, Portland, OR
- Joe Artuso, Berwyn, PA
- H. Joachim Deeg, Seattle, WA
- R. George Angula, Sun Lakes, AZ
- Mary K. Parkinson, Annapolis, MD
- David Bowen, North Yorkshire, UK
- Timothy McClusky, Charlotte, NC
- Adele C. Buzzetti, New York, NY
- Marlene Strohl, San Marcos, CA
- Cars 4 Causes, Ventura, CA
- Jeannette R. Russell, Springfield, MA
- Thomas & Linda Eberhardt, Conroe, TX
- Colin Orrett, Sunrise, FL
- Marla J. Miller, Priest River, ID
- Al Sheahen, Van Nuys, CA
- Neil and Alice Waldow, Kents Store, VA
- Philip L. Gore, Tarzana, CA
- Andrew O. Feuerstein, Brooklyn, NY
- Bob & Andi Wilner, Sherman Oaks, CA
- Samuel & Geraldine Fineman, Boca Raton, FL
- Claude & Margaret Guyard, Jupiter, FL
- Norma Lee Corbin, Clairton, PA
- Leonard Jewier, Washington, DC
- John & Marcelle Lay, Madisonville, KY
- Raymond & Irene Silka, Manhasset, NY
- Annie G. Roberts, Gainesville, FL
- William & Barbara Keyes, North Port, FL
- Fred Burns, Vero Beach, FL
- Ron Dreben, Washington, DC
- Sally Calvert, Chesterfield, VA
- David Pressley, Taeerre Haute, IN
- Gerry Meyer, Great Falls, MT
- Betsy Burgess, Portola Valley, CA
- Steven Gore, Baltimore, MD
- Robert Wanderman, Atlanta, GA
- Stephen Nimer, New York, NY
- Michael & Penny Zimring, Ellicott City, MD
- Ruth Lublin, Bryn Mawr, PA
- John and Betty Frey, Allentown, PA
- Barry F. Johnson, Dallas, TX
- Bessie Betty Sturm, Brooklyn, NY
- John & Sally Mac Arthur, Silver Spring, MD
- JRM Financial Associates, LLC, Flemington, NJ

Next Generation Bookkeeping, LLC, Flemington, NJ
Michael Losow, Durham, NC
Shirley E. Opitz, Monroeville, PA
Angelo Dituri, Babylon, NY
Sam & Ruth Rosenblum, Hackensack, NJ
Dave and Donna Bunton, Arlington, VA
George Mako, Forked River, NJ
Janine Cruz, Florham Park, NJ
Raymond & Prudence Malles, Bonita Springs, FL
Robert & Elizabeth Weiss, Fort Myers, FL
Ekaterini & Anastasia Fokas, Astoria, NY
Giuseppe Mallimo, Cypress, TX
Leonard & Kathleen Paske, Minong, WI
Thomas and Sheila, Martin, Fairfax, VA
Joseph & C. Ellen Walker, Sebring, FL
Betty J. Mincemosay, State College, PA
Francis Rausch, Newburgh, IN
Scott Slotterbeck, Sacramento, CA
Marie Sounder, Fort Lauderdale, FL
David M. Cohn, Blue Bell, PA
Bob & Joan Sadoff, Huntingdon Valley, PA
Herman & Elaine Blecker, Feasterville, PA
James & Margaret Cannon, Secane, PA
Edward Daniels, Raleigh, NC
Donna Wolff, New York, NY
Robert and Bette Donoho, Wheaton, IL
Ronald E. Jerro, Great Falls, VA
Marilyn E. Gillum, Wellsboro, PA
Wendell Croom, Little Rock, AR
Daniel and Sharon Cica, Bay Village, OH
Donna J. O’Hare, Traverse City, MI
Katherine L. McBride, Browns Summit, NC
A Living Endowment

Many families are affected by living with the reality of MDS. There is an extraordinary way to contribute to the MDS Foundation and support our mission of working as a resource for patients, families, and healthcare professionals.

A commitment to donate to the Foundation on occasions of loss, birthdays, and anniversary remembrances can be made. Honor your friends or family members on these occasions with a donation, and the MDS Foundation will send an acknowledgment to the recipient, recognizing the occasion.

A Living Endowment donation has been made in honor of:

Eric Kaden
This donation was submitted by:
Susan Gerber
Tomkins Cove, NY

A Living Endowment donation has been made in honor of:

Dr. James Wade
This donation was submitted by:
Carol Wise

A Living Endowment donation has been made in honor of:

Dr. Stephen Nimer
This donation was submitted by:
Barry Cooper
Brooklyn, NY

A Living Endowment donation has been made in honor of:

Robert Amey
This donation was submitted by:
Braylon Edwards
Troy, MI

A Living Endowment donation has been made in honor of:

Peggy Silvergleid
This donation was submitted by:
Jordan Silvergleid
Austin, Texas

A Living Endowment donation has been made in honor of:

Mr. & Mrs. Tom Eberhardt
This donation was submitted by:
Sally Calvert
Chesterfield, VA

A Living Endowment donation has been made in honor of:

Dr. & Mrs. Brad Hill
This donation was submitted by:
Sally Calvert
Chesterfield, VA

A Living Endowment donation has been made in honor of:

Aldeane Soot
This donation was submitted by:
Eric P. Bohannon
Battle Ground, WA

A Living Endowment donation has been made in honor of:

Mary Lou Derose
This donation was submitted by:
Stephen Derose
Los Angeles, CA

A Living Endowment donation has been made in honor of:

Ms. Enid Rottenberg
This donation was submitted by:
Edward K. Blodnick
Garden City, NY

A Special Thank You to
Gabrielle’s Angel Foundation
for Cancer Research

We would like to especially thank Gabrielle’s Angel Foundation for Cancer Research for their generous grant in the amount of $25,000.00 in support of young investigators through the MDS Foundation.
In Memoriam

A memorial fund has been established in the name of Mrs. Betty Louise Chappel Armacost
Donations have been made in Mrs. Armacost's memory by:
Gary and Stacia Featherston, Carmel, TN

A memorial fund has been established in the name of Ms. Rose Marie Austin
Donations have been made in Ms. Austin's memory by:
Janet Discopoio, Wicoff, CT

A memorial fund has been established in the name of Ms. Cathy Jean Avants
Donations have been made in Ms. Avants' memory by:
Nancy A. Smith
Surprise, AZ
Carl and Kathy Moore
Phoenix, AZ
Ana Perez
Garden City, GA
Gordon, GA
Glendale, AZ
Auburn Hills, MI

A memorial fund has been established in the name of Dr. Henry Banal
Donations have been made in Dr. Banal's memory by:
Talia Tanick, Minnetonka, MN

A memorial fund has been established in the name of Mr. Harold Baron
Donations have been made in Mr. Baron's memory by:
Whitey and Denise Berniker
Montrose, NY
Les Wallman
Jackson, NJ
Bernie and Nora Friedman
Harvey and Muriel Fertig
Boca Raton, FL
Brooklyn, NY

A memorial fund has been established in the name of Mr. Tito Bastianello
Donations have been made in Mr. Bastianello’s memory by:
Francesca Bastianello Camerino, Venedig, Italy

A memorial fund has been established in the name of Ms. Dorothy Bayer
Donations have been made in Ms. Bayer's memory by:
David L. Bayer, Bourbonsnaius, IL

A memorial fund has been established in the name of Ms. Kyong Cha Benton
Donations have been made in Ms. Benton's memory by:
Milford and Marilyn Bennett
Chatsworth, GA
Sydney Daly
Chatsworth, GA
Cynthia L. Young
Lakewood, CA
Annette D. Young
Kansas City, MO
Doug & Georgina O’Quinn
Chatsworth, GA

A memorial fund has been established in the name of Mr. Michael Brecker
Donations have been made in Mr. Brecker's memory by:
Darryl Pitt, New York, NY

A memorial fund has been established in the name of Mr. L. Ronald Brown
Donations have been made in Mr. Brown's memory by:
Gail Doxtader, Portland, OR

A memorial fund has been established in the name of Mr. Clem Cahall
Donations have been made in Mr. Cahall's memory by:
Claire-Elizabeth Sloan, Portland, OR

A memorial fund has been established in the name of Mr. Colin Campbell
Donations have been made in Mr. Campbell’s memory by:
Helen McGennis
Co. Wicklow, Ireland

A memorial fund has been established in the name of Mr. Bill Charnow
Donations have been made in Mr. Charnow’s memory by:
Libby Falcon, Brooklyn, NY

A memorial fund has been established in the name of Ms. Carolyn Clayton-Pestor
Donations have been made in Ms. Clayton-Pestor’s memory by:
Richard and Judy Ferrandino
Coto de Caza, CA
Douglas Green
Anaheim Hills, CA
Howard and Barbara Fiprin
Anaheim Hills, CA
Shirley C. Bernder
Tustin, CA
Randy Pestor and JoAnne Speers
Sacramento, CA
Beta Omicron Master
Anaheim, CA
Peggy Broad, Gail Cohn, Barbara Fiprin, Mary Lou Friedt, Lillian Grammer, Gloria Hennessay, Lois Mitchell, Joan North, Pauline Paine, Shirley Pigley & Sandy Reed, Mary Jane Marone
Orange, CA

A memorial fund has been established in the name of Mr. John J. Corona
Donations have been made in Mr. Corona's memory by:
Angelo R. Rolando, Rocky Hill, CT

A memorial fund has been established in the name of Mr. Daniel "Dan" Crowley
Donations have been made in Mr. Crowley's memory by:
N.K. Rhangley
United Kingdom
S. Crowley
United Kingdom
J. Booth
United Kingdom
Mrs. D. Buttershaw
Felpham, Bognor Regis
United Kingdom
J.S. Gorrnyn
United Kingdom
Mrs. Hobby
United Kingdom

A memorial fund has been established in the name of Mr. Andreas Fokas
Donations have been made in Mr. Fokas’ memory by:
Anastasia Fokas, Astoria, NY

A memorial fund has been established in the name of Mr. Jack Lambert Frost
Donations have been made in Mr. Frost's memory by:
Van May, Lubbock, TX
A memorial fund has been established in the name of **Ms. Elaine Frye**
Donations have been made in Ms. Frye’s memory by:
- E.C. Frye, Jr., Longview, TX
- D. Cucuzza, New Haven, CT

A memorial fund has been established in the name of **Ms. Jennifer Sharon Gallagher-Welch**
Donations have been made in Ms. Welch’s memory by:
- Sara Edith Gallagher, Dayton, OH

A memorial fund has been established in the name of **Mrs. Judie Meyer Geer**
Donations have been made in Mrs. Geer’s memory by:
- Carol Mitchell, Raleigh, NC
- Sandra Ward, Sarasota, FL
- Frank and Joanne Wootton, Durham, NC
- Donald Rafferty, Manor Valley, AZ
- Gerald and Lynn Woolard, Raleigh, NC
- Mickey Costello, Dallas, TX
- Judith Calhoun, Raleigh, NC
- Cory and Katie Menees, Atlanta, GA
- Jonathan. Parsh Peddick, Greensboro, NC

A memorial fund has been established in the name of **Mr. Clyde A. Hall**
Donations have been made in Mr. Hall’s memory by:
- George and Karen Pfeffer, Harmony, PA
- Michael and Linda Klein, Mason, OH
- Raymond & Sharon Lindsay, Wampum, PA

A memorial fund has been established in the name of **Mrs. Ann Leslie Cosenza Hallberg**
Donations have been made in Mrs. Hallberg’s memory by:
- Mary K. Snyder, Hamden, CT
- Drew Cucuzza, New Haven, CT

A memorial fund has been established in the name of **Ms. Mary Elizabeth Hanson**
Donations have been made in Ms. Hanson’s memory by:
- Anna Erlandson, Libby, MT

A memorial fund has been established in the name of **Mr. William Haskell**
Donations have been made in Mr. Haskell’s memory by:
- Ronald and Joan Moore, Rowland Street Garage, Inc., Ballston Spa, NY
- Bob & Rae (Nancy) Andrews, Rowland Street Garage, Inc., Ballston Spa, NY

A memorial fund has been established in the name of **Mr. Martin Heiss**
Donations have been made in Mr. Heiss’ memory by:
- Robert Busch, East Meadow, NY

A memorial fund has been established in the name of **Mr. Andrew E. Helmich**
Donations have been made in Mr. Helmich’s memory by:
- Günther and Heidi Helmich, Denmark

A memorial fund has been established in the name of **Mr. Abraham J. Hoffman**
Donations have been made in Mr. Hoffman’s memory by:
- Fred Hoffman, Rockville, MD
- Bob and Kaye Brown, Richmond, VA

A memorial fund has been established in the name of **Ms. Laurie Hoffman**
Donations have been made in Mrs. Hoffman’s memory by:
- Gary Hoffman, Oregon City, OR

A memorial fund has been established in the name of **Mrs. Virginia Ann Jordan**
Donations have been made in Mrs. Jordan’s memory by:
- George and Patricia Marr, Germantown, TN
- Elinor Haligian, Timonium, MD
- Donald and Joan Behringer, Huntersville, NC

A memorial fund has been established in the name of **Ms. Thelma Joseph**
Donations have been made in Ms. Joseph’s memory by:
- Timothy McClasky, Charlotte, NC

A memorial fund has been established in the name of **Ms. Irene Katz**
Donations have been made in Ms. Katz’ memory by:
- Jane G. Evans, Pittsford, NY

A memorial fund has been established in the name of **Ms. Jennifer Sharon Gallagher-Welch**
Donations have been made in Ms. Gallagher-Welch’s memory by:
- Jodi Smallwood, Upper Marlboro, MD

A memorial fund has been established in the name of **Mrs. Eleanor Rita Gazo Kranchick**
Donations have been made in Mrs. Kranchick’s memory by:
- Bob & Rae (Nancy) Andrews, Fairfax, VA
- Lieutenant W. Bruce Walters, Upper Marlboro, MD

A memorial fund has been established in the name of **Mr. Peter J. Kennedy**
Donations have been made in Mr. Kennedy’s memory by:
- Phil and Maria Welch, Lincroft, NJ

A memorial fund has been established in the name of **Mrs. American “Ina” Kulka**
Donations have been made in Mrs. Kulka’s memory by:
- John and Judy Herrmert,  paperwood, NJ

A memorial fund has been established in the name of **Mr. Herb Kupersmit**
Donations have been made in Mr. Kupersmit’s memory by:
- Peggy Cherkesky, Pittsford, NY

A memorial fund has been established in the name of **Ms. Elaine Frye**
Donations have been made in Ms. Frye’s memory by:
- E.C. Frye, Jr., Longview, TX

A memorial fund has been established in the name of **Mr. Clyde A. Hall**
Donations have been made in Mr. Hall’s memory by:
- George and Karen Pfeffer, Harmony, PA
- Michael and Linda Klein, Mason, OH
- Raymond & Sharon Lindsay, Wampum, PA

A memorial fund has been established in the name of **Mrs. Ann Leslie Cosenza Hallberg**
Donations have been made in Mrs. Hallberg’s memory by:
- Mary K. Snyder, Hamden, CT
- Drew Cucuzza, New Haven, CT

A memorial fund has been established in the name of **Ms. Mary Elizabeth Hanson**
Donations have been made in Ms. Hanson’s memory by:
- Anna Erlandson, Libby, MT

A memorial fund has been established in the name of **Mr. William Haskell**
Donations have been made in Mr. Haskell’s memory by:
- Ronald and Joan Moore, Rowland Street Garage, Inc., Ballston Spa, NY
- Bob & Rae (Nancy) Andrews, Rowland Street Garage, Inc., Ballston Spa, NY

A memorial fund has been established in the name of **Mr. Martin Heiss**
Donations have been made in Mr. Heiss’ memory by:
- Robert Busch, East Meadow, NY

A memorial fund has been established in the name of **Mr. Andrew E. Helmich**
Donations have been made in Mr. Helmich’s memory by:
- Günther and Heidi Helmich, Denmark

A memorial fund has been established in the name of **Mr. Abraham J. Hoffman**
Donations have been made in Mr. Hoffman’s memory by:
- Fred Hoffman, Rockville, MD
- Bob and Kaye Brown, Richmond, VA

A memorial fund has been established in the name of **Ms. Laurie Hoffman**
Donations have been made in Mrs. Hoffman’s memory by:
- Gary Hoffman, Oregon City, OR

A memorial fund has been established in the name of **Mrs. Virginia Ann Jordan**
Donations have been made in Mrs. Jordan’s memory by:
- George and Patricia Marr, Germantown, TN
- Elinor Haligian, Timonium, MD
- Donald and Joan Behringer, Huntersville, NC

A memorial fund has been established in the name of **Ms. Thelma Joseph**
Donations have been made in Ms. Joseph’s memory by:
- Timothy McClasky, Charlotte, NC

A memorial fund has been established in the name of **Ms. Irene Katz**
Donations have been made in Ms. Katz’ memory by:
- Jane G. Evans, Pittsford, NY
A memorial fund has been established in the name of Mr. Roy Kussner
Donations have been made in Mr. Kussner’s memory by:
Sy and Sandi Kofsky
Farmington, CT
Robert and Shirley Geron
Newington, CT
Art and Susan Israel
West Hartford, CT
Karen MacVeigh
Gulfport, CT
Richard and Judy Levy
Bloomingfield, CT
John and Kathleen Tilki
Derby, CT
Barbara Zimmerman
Indian Land, SC
Robert and Pat Lapp
Paso Robles, CA
Donations have been made in Ms. Lapp’s memory by:
Ron and Pat Lapp, Paso Robles, CA

A memorial fund has been established in the name of Mr. Jerry Latimer
Donations have been made in Mr. Latimer’s memory by:
Julia Bergen, Flora Park, NY
Meril Schuman

A memorial fund has been established in the name of Mrs. Irena R. Pawlik Litzenberger
Donations have been made in Mrs. Litzenberger’s memory by:
Leonard Litzenberger, Allentown, PA

A memorial fund has been established in the name of Dr. Grace Yu-Sheng Lo
Donations have been made in Dr. Lo’s memory by:
Carole K. Tuttle
Fort Collins, CO
Yulan C. Tong
Walnut Creek, CA
Nina Chang
Midland, MI
Madison, WI
I-Cheng Chang, Libertyville, IL

A memorial fund has been established in the name of Ms. Alice Irene Lockett
Donations have been made in Ms. Lockett’s memory by:
Dave and Pat Houck
Portland, OR
Marlyn Gillaspie
Portland, OR

A memorial fund has been established in the name of Mr. Robert W. Love
Donations have been made in Mr. Love’s memory by:
Bucks County Iron MC, Feasterville, PA

A memorial fund has been established in the name of Mr. Jim Lyall
Donations have been made in Mr. Lyall’s memory by:
Ellen Hart, Leesburg, FL

A memorial fund has been established in the name of Ms. Florence Malicunco
Donations have been made in Ms. Malicunco’s memory by:
Angelo and Rose Stalikos, Hazlet, NJ

A memorial fund has been established in the name of Ms. Carrie Kirkland Martin
Donations have been made in Ms. Martin’s memory by:
Elizabeth Ballard, Houston, TX

A memorial fund has been established in the name of Mr. Gary Eugene Martin
Donations have been made in Mr. Martin’s memory by:
Eric Prater
Buena Park, CA
Richard Yaikutoff
Linda, CA

A memorial fund has been established in the name of Ms. Grace S. Miyawaki
Donations have been made in Ms. Miyawaki’s memory by:
Mary Miyawaki, Honolulu, HI

A memorial fund has been established in the name of Mr. Lavere C. Munn
Donations have been made in Mr. Munn’s memory by:
Gary Munn, Dalton, GA

A memorial fund has been established in the name of Mr. Chuck Navasky
Donations have been made in Mr. Navasky’s memory by:
Jerry and Renee Green, Boynton Beach, FL

A memorial fund has been established in the name of Mrs. Lina Nessouli
Donations have been made in Mrs. Nessouli’s memory by:
Barry and Caryn Kriegel
Atlanta, GA
Steven & Melinda Wertheim
Atlanta, GA
Yazan and Rimah Houssami
Atlanta, GA
Lori, Gena, Kolin, Blake Simon
Atlanta, GA

A memorial fund has been established in the name of Mr. Stan Nossett
Donations have been made in Mr. Nossett’s memory by:
Rich and Deb Wilson, Susan Ann Vick
Fort Wayne, IN

A memorial fund has been established in the name of Mrs. Arlene O’Donnell
Donations have been made in Mrs. O’Donnell’s memory by:
James J. O’Donnell, III
Ocean City, NJ
Charlene Slider
Perkasie, PA

A memorial fund has been established in the name of Mr. Michael Oertelt
Donations have been made in Mr. Oertelt’s memory by:
Rhett Whitaker, Pittsburgh, PA

A memorial fund has been established in the name of Ms. Muriel Oliverio
Donations have been made in Ms. Oliverio’s memory by:
Joyce Hammer, San Antonio, TX

A memorial fund has been established in the name of Mrs. Mary Ann Opanowicz
Donations have been made in Mrs. Opanowicz’ memory by:
Arthur Opanowicz, Jensen Beach, FL

A memorial fund has been established in the name of Mr. Ronald Pare
Donations have been made in Mr. Pare’s memory by:
James Phalon, Newato, CA

A memorial fund has been established in the name of Mr. Martin H. Park
Donations have been made in Mr. Park’s memory by:
Dr. & Mrs. Louis and Jacqueline Sojka
Elkhorn, NE
Joelene Nielsen
Columbus, NE
William C. Taylor
Richmond, VA
John and Mary Kay Peck
Columbus, NE
Bob and Norma Hudson
Columbus, NE
Steven Hinchcliff
Omak, NE
Rodney and Cathy Hill
Loveland, CO
Vee Hockerberger
Columbus, NE
Lillian Schroeder
Columbus, NE
John and Carol Wolf
Issaquah, WA
Jerome and Imogene Jilek
Columbus, NE
Colin and Pat Hackley
Lincoln, NE
Cindy T. Whiteley
Wilson, NC
John and Helena Alexander
Hertfordshire, UK
Ira Zilst
Richmond, VA
Davd and Kathleen Weibold
Shenandoah, IA
Peggy L. Frieze
Aurora, CO
R. and J. Lucas
Newport Beach, CA

A memorial fund has been established in the name of Mr. Harvey Pearman
Donations have been made in Mr. Pearman’s memory by:
Kenneth and Cynthia Eckstein, Bridgewater, CT

A memorial fund has been established in the name of Mr. Alejandro Perez
Donations have been made in Mr. Perez’ memory by:
Ana Perez, Glendale, AZ
A memorial fund has been established in the name of Mr. Michael Plotka
Donations have been made in Mr. Plotka’s memory by:
Tom and Mary Toth  Robert and Denise Abbott
Toledo, OH  Toledo, OH
Tom and Sue Wojnowski, Toledo, OH

A memorial fund has been established in the name of Mr. Ralph Reisig
Donations have been made in Mr. Reisig’s memory by:
Levow & Associates, PA  Charlie and Susan Clark
Cherry Hill, NJ  Freehold, NJ
Samuel L. Sachs & Friends  Joseph and Tracy Call
East Windsor, NJ  Atlantic Highlands, NJ
Thomas F.S. Fokey  Arnold and Temma Fishman
Spartan Lake, NJ  Millford Lakes, NJ
David J. Foley  Mr. and Mrs.
Kearnsburg, NJ  W. Beutlemiller
Joan F.D. West  David and Nancy Reisig
Cherry Hill, NJ  Feasterville Trevose, PA

A memorial fund has been established in the name of Mr. Antony Rubino
Donations have been made in Mr. Rubino’s memory by:
Tim Schroeder, John Staliknecht, Ron LoRusso, Bill Sarnowski
Wanaque, NJ  Raquel Graham

A memorial fund has been established in the name of Mr. Robert Santhay
Donations have been made in Mr. Santhay’s memory by:
The Kaplicer Family  David S. Carroll
Livingston, NJ  New York, NY
AXP Corporate Securities Group, New York, NY

A memorial fund has been established in the name of Mr. Carlos M. Santiago
Donations have been made in Mr. Santiago’s memory by:
Veronica Giordano, Huntersville, NC

A memorial fund has been established in the name of Mr. Charles Sayer
Donations have been made in Mr. Sayer’s memory by:
Michael Sayer, Linden, NJ  Rich Lord, Linden, NJ

A memorial fund has been established in the name of Mr. Robert L. Schriefels
Donations have been made in Mr. Schriefels’ memory by:
William Schriefels, Sartell, MN

A memorial fund has been established in the name of Mrs. Arlene Schwab
Donations have been made in Mrs. Schwab’s memory by:
Paul Croet, Long Beach, CA

A memorial fund has been established in the name of Mr. Chester E. Shrouder
Donations have been made in Mr. Shrouder’s memory by:
Don Bullian Gibson  Jerry and Susan Henderson
Dallas, TX  Ardmore, OK
Jerry and Cindy Dodds, Mansville, OK

A memorial fund has been established in the name of Mr. Agustin Sierra
Donations have been made in Mr. Sierra’s memory by:
Margaret Cain, Alexandria, VA

A memorial fund has been established in the name of Mr. Jerry David Sims
Donations have been made in Mr. Sims’ memory by:
Chris Birch  Catherine Macke
St. Charles, MO  St. Louis, MO
Mary Allen  Danny and Deiones
Fortville, MO  Melloway, Columbia, MO

A memorial fund has been established in the name of Ms. Carol May Smith
Donations have been made in Ms. Smith’s memory by:
Marilyn Nelson  Robert W. Brown
Pearl River, NY  Altus Insurance Agency
Catherine Nelson  Sarasota, FL
Franklin Square, NY  Beth Gardell
John Adamik  West Kingston, RI
Heights, NY

A memorial fund has been established in the name of Mr. Donald A. Smith
Donations have been made in Mr. Smith’s memory by:
A&B Homes, Inc.  Mr. & Mrs. David St. Ledger
Honesdale, PA  Mechanicsburg, PA
William and Mary Schutt  Dr. Smith’s family
Jefferson Township, PA

A memorial fund has been established in the name of Mr. Mark Smith, RN
Donations have been made in Mr. Smith’s memory by:
Lincoln, West Orange, NJ

A memorial fund has been established in the name of Ms. Wanda Sobieski
Donations have been made in Ms. Sobieski’s memory by:
Bill and Ann Cochran  Bill and Ann Cochran
Valley, AZ  Valley, AZ

A memorial fund has been established in the name of Dr. Thomas E. Sooy
Donations have been made in Dr. Sooy’s memory by:
Diane M. Sooy  Robert T. Mowry
Ellict City, MD  Jacksonville, FL

A memorial fund has been established in the name of Mr. Raymond E. Thomas
Donations have been made in Mr. Thomas’ memory by:
Alyssa Ligammbani  Nancy and Allen Cavender
Staten Island, NY  Chapel Hill, NC
Claire Rider  Sara Lynn Tolar
Centerton, CT  Rockville, MD

A memorial fund has been established in the name of Mr. Robert Edward Thomas
Donations have been made in Mr. Thomas’ memory by:
Joy J. Conners  Sally Stearns
Beltville, MD  Chapel Hill, NC

A memorial fund has been established in the name of Mr. William Thomas
Donations have been made in Mr. Thomas’ memory by:
Amy Gotham  Sally Thomas
Lake Placid, NY  South Colton, NY

A memorial fund has been established in the name of Mrs. Jeanette Toth
Donations have been made in Mrs. Toth’s memory by:
Dave and Donna Bunton  Joseph M. Toth
Arlington, VA  Manalapan, NJ

A memorial fund has been established in the name of Mr. Joseph A. Vaccaro
Donations have been made in Mr. Vaccaro’s memory by:
George and Sue Triog  Dee Vaccaro
Glendale, AZ  Timonium, MD
Donald Breen  Theresa, NY

A memorial fund has been established in the name of Ms. Lois VanHorn
Donations have been made in Ms. VanHorn’s memory by:
Tim and Connie Wettrick  Mercer Island, WA

A memorial fund has been established in the name of Mrs. Grace Vieraits
Donations have been made in Mrs. Vieraits’ memory by:
Melinda Mann  Brookline, MA

A memorial fund has been established in the name of Mr. John Walsh
Donations have been made in Mr. Walsh’s memory by:
Ed and Ronny Wahl  Naples, FL

A memorial fund has been established in the name of Mr. Derek Harold Wells
Donations have been made in Mr. Wells’ memory by:
Wendy Wells  Suffolks, UK

A memorial fund has been established in the name of Mrs. Eleanor L. “Elle” Wright
Donations have been made in Mrs. Wright’s memory by:
Michigan Commerce Bank  Ann Arbor, MI

A memorial fund has been established in the name of Mr. David Yoh
Donations have been made in Mr. Yoh’s memory by:
Drs. Bert and Sally Russell  David and Nancy Ristow
Sylvia Ostrow, Miami, FL  Ada, MI

A memorial fund has been established in the name of Mrs. Lisa Post Zahler
Donations have been made in Mrs. Zahler’s memory by:
STAC (Students and Teachers Against Cancer)  Sewanhaka Central High School
Staten Island, NY  Floral Park, NY
The Foundation’s Board of Directors

John M. Bennett, MD
Professor of Medicine, Emeritus
Laboratory Medicine and Pathology
University of Rochester Medical Center
Rochester, New York, U.S.A.

David T. Bowen, MD
Professor of Hematology
St. James’s University Hospital
St. James’s Institute of Oncology
Leeds, United Kingdom

Mario Cazzola, MD
Professor of Hematology
University of Pavia
School of Medicine
Head, Department of Hematology
IRCCS Policlinico S. Matteo
Pavia, Italy

Theo J.M. de Witte, MD, PhD
Professor of Hematology
University Medical Center
Nijmegen St. Radboud
Nijmegen, The Netherlands

Pierre Fenaux, MD
Professor of Hematology
Hôpital Avicenne
University Paris 13
Bobigny, France

Peter L. Greenberg, MD
Professor of Medicine/Hematology
Stanford University School of Medicine
Stanford, California, U.S.A.

Eva Hellström-Lindberg, MD, PhD
Associate Professor of Hematology
Karolinska Institutet
Institution for Medicine
Huddinge University Hospital
Stockholm, Sweden

Sandra E. Kurtin, RN, MS, AOCN, ANP-C
Hematology/Oncology Nurse Practitioner
Arizona Cancer Center
Clinical Assistant Professor of Nursing
Clinical Assistant Professor of Medicine
University of Arizona
Tucson, Arizona, U.S.A.

Alan F. List, MD
Executive Vice President
Physician-in-Chief, and Morsani Chair
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, U.S.A.

John Molle, CPA
JRM Financial Associates, LLC
Flemington, New Jersey, U.S.A.

Ghulam J. Mufti, MD
Professor of Haematology
University of London
King’s College Hospital
London, United Kingdom

Charlotte M. Niemeyer, MD
Professor of Pediatrics
University Children’s Hospital
Freiburg, Germany

Stephen D. Nimer, MD
Head, Division of Hematologic Oncology
Memorial Sloan-Kettering Cancer Center
New York, New York, U.S.A.

Robert J. Weinberg, Esq.
Pepper Hamilton LLP
Philadelphia, Pennsylvania, U.S.A.

Emeritus Members
Terry Hamblin, DM, FRCP, FRC Path
Bournemouth, United Kingdom

Franz Schmalzl, MD
Innsbruck, Austria

MDS Foundation Information

Become a Member

The MDS Foundation would like to have you as a member. Membership is US$50 a year for physicians and other professionals. Patients, their families, and others interested in MDS may join at the reduced rate of $35.

Membership benefits include issues of the MDS News, a special subscription rate of $119.00 for Leukemia Research (a substantial discount from the current institutional subscription rate of $2,373), and the worldwide Centers of Excellence patient referral service.

Please visit us at: www.mds-foundation.org.

Ways to Support the Foundation’s Work All Year Long

If you wish to support the work of the Foundation in the battle against MDS, please remember us and consider donating all year long.

Every penny helps. All donations are tax-deductible.

The MDS Foundation is very grateful for the heartfelt support of its donors. Our work as a non-profit organization depends on public funding, and we hope that you include us as one of the worthy charities that you support this year. We have enclosed a pre-addressed contribution envelope to make it easier. You will receive an MDS Foundation enamel lapel pin in appreciation of your donation.

Thank you for your support.